Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis
Copyright policy )Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis
Abstract Objective To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. Methods EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor−related epilepsy [BTRE], and traumatic brain injury−related epilepsy [TBIE]). Results At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively. Conclusions BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.
- UCB Pharma (United Kingdom) United Kingdom
- Goethe University Frankfurt Germany
- Comunidad de Madrid Spain
- St Vincent's Hospital Australia
- White Rose Consortium: University of Leeds; University of Sheffield; University of York United Kingdom
Male, Adult, Etiology, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Central Nervous System Agents::Anticonvulsants, Adolescent, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Aged [MeSH] ; Mental Disorders/drug therapy [MeSH] ; Epilepsy/drug therapy [MeSH] ; Pyrrolidinones/therapeutic use [MeSH] ; Male [MeSH] ; Real world ; Mental Disorders/etiology [MeSH] ; Comorbidity [MeSH] ; Epilepsy/epidemiology [MeSH] ; Effectiveness ; Adolescent [MeSH] ; Female [MeSH] ; Adult [MeSH] ; Humans [MeSH] ; Treatment Outcome [MeSH] ; Middle Aged [MeSH] ; Anticonvulsants/adverse effects [MeSH] ; Anticonvulsants/therapeutic use [MeSH] ; Pyrrolidinones/adverse effects [MeSH] ; Mental Disorders/epidemiology [MeSH] ; Young Adult [MeSH] ; Brivaracetam ; Comorbidity ; Etiology ; Original Communication ; Tolerability, Otros calificadores::Otros calificadores::/uso terapéutico, 610, Effectiveness, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::epilepsia, Comorbidity, DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Epilepsy, Anticonvulsius - Ús terapèutic, Young Adult, 616, Humans, Aged, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Original Communication, Epilepsy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Mental Disorders, Real world, Middle Aged, Tolerability, Epilèpsia - Tractament, Pyrrolidinones, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Treatment Outcome, Brivaracetam, Avaluació de resultats (Assistència sanitària), COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos del sistema nervioso central::anticonvulsivantes, Female, Anticonvulsants
Male, Adult, Etiology, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Central Nervous System Agents::Anticonvulsants, Adolescent, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Aged [MeSH] ; Mental Disorders/drug therapy [MeSH] ; Epilepsy/drug therapy [MeSH] ; Pyrrolidinones/therapeutic use [MeSH] ; Male [MeSH] ; Real world ; Mental Disorders/etiology [MeSH] ; Comorbidity [MeSH] ; Epilepsy/epidemiology [MeSH] ; Effectiveness ; Adolescent [MeSH] ; Female [MeSH] ; Adult [MeSH] ; Humans [MeSH] ; Treatment Outcome [MeSH] ; Middle Aged [MeSH] ; Anticonvulsants/adverse effects [MeSH] ; Anticonvulsants/therapeutic use [MeSH] ; Pyrrolidinones/adverse effects [MeSH] ; Mental Disorders/epidemiology [MeSH] ; Young Adult [MeSH] ; Brivaracetam ; Comorbidity ; Etiology ; Original Communication ; Tolerability, Otros calificadores::Otros calificadores::/uso terapéutico, 610, Effectiveness, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::epilepsia, Comorbidity, DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Epilepsy, Anticonvulsius - Ús terapèutic, Young Adult, 616, Humans, Aged, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Original Communication, Epilepsy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Mental Disorders, Real world, Middle Aged, Tolerability, Epilèpsia - Tractament, Pyrrolidinones, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Treatment Outcome, Brivaracetam, Avaluació de resultats (Assistència sanitària), COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos del sistema nervioso central::anticonvulsivantes, Female, Anticonvulsants
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).11 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!